These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 29230548)
21. [Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. Bernadach M; Lapeyre M; Dillies AF; Miroir J; Moreau J; Kwiatkowski F; Pham-Dang N; Saroul N; Durando X; Biau J Cancer Radiother; 2019 Jul; 23(4):273-280. PubMed ID: 31138520 [TBL] [Abstract][Full Text] [Related]
22. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649 [TBL] [Abstract][Full Text] [Related]
23. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605 [TBL] [Abstract][Full Text] [Related]
24. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma. Yang WC; Chen CH; Tang JY; Wu CF; Liu YC; Sun Y; Lin SF Anticancer Res; 2014 Jul; 34(7):3765-73. PubMed ID: 24982400 [TBL] [Abstract][Full Text] [Related]
25. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394 [TBL] [Abstract][Full Text] [Related]
26. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499 [TBL] [Abstract][Full Text] [Related]
27. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Sher DJ; Posner MR; Tishler RB; Sarlis NJ; Haddad RI; Holupka EJ; Devlin PM Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e813-8. PubMed ID: 21300455 [TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study. Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F Oncology; 2013; 84(4):251-4. PubMed ID: 23428719 [TBL] [Abstract][Full Text] [Related]
29. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ; Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064 [TBL] [Abstract][Full Text] [Related]
30. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma. Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220 [TBL] [Abstract][Full Text] [Related]
31. Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology. Alterio D; Cossu Rocca M; Russell-Edu W; Dicuonzo S; Fanetti G; Marvaso G; Preda L; Zorzi S; Verri E; Nole' F; Jereczek-Fossa BA Med Oncol; 2017 May; 34(5):86. PubMed ID: 28391578 [TBL] [Abstract][Full Text] [Related]
32. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. Ahn PH; Machtay M; Anne PR; Cognetti D; Keane WM; Wuthrick E; Dicker AP; Axelrod RS Am J Clin Oncol; 2018 May; 41(5):441-446. PubMed ID: 27391356 [TBL] [Abstract][Full Text] [Related]
33. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Katori H; Tsukuda M; Watai K Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160 [TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566 [TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131 [TBL] [Abstract][Full Text] [Related]
36. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck. Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552 [TBL] [Abstract][Full Text] [Related]
37. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL; N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012 [TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study. Ham JC; van Herpen CML; Driessen CML; van der Graaf WTA; Husson O Oral Oncol; 2019 Sep; 96():105-112. PubMed ID: 31422201 [TBL] [Abstract][Full Text] [Related]
39. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]